Evidence map›Paper›PMID 40437039›Full record

SynthesisEye (London, England)2025

Non-surgical interventions for proliferative vitreoretinopathy-a systematic review.

Guy Hunter, Nairn Maclean, Stephanie Watson, Marcus Colyer, James Leong, Rupesh Agrawal, Scott F McClellan, Kyle E Miller, Fasika A Woreta, Matthew C Caldwell and 14 more

Abstract readSystematic Review
In one paragraph

Synthesis in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Guy HunterInstitute of Naval Medicine, Gosport, UK. guy.hunter@nhs.net.ORCID http://orcid.org/0000-0002-8057-3364
Nairn MacleanArmy Medical Services, Camberley, UK.
Stephanie WatsonSave Sight Institute, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-6699-1765
Marcus ColyerUniformed Services University of the Health Sciences, Bethesda, MD, USA.
James LeongSydney Eye Hospital, Sydney, NSW, Australia.
Rupesh AgrawalNational Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.ORCID http://orcid.org/0000-0002-6662-5850
Scott F McClellanVision Center of Excellence, Research & Development Directorate (J-9), Defence Health Agency, Baltimore, MD, USA.
Kyle E MillerVision Center of Excellence, Research & Development Directorate (J-9), Defence Health Agency, Baltimore, MD, USA.
Fasika A WoretaWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew C CaldwellDepartment of Ophthalmology, San Antonio Uniformed Services Health Education Consortium, San Antonio, TX, USA.
Tom WilliamsonDepartment of Engineering and Biological Sciences, University of Surrey, Surrey, UK.ORCID http://orcid.org/0000-0002-1879-449X
William GensheimerWhite River Junction Veterans Administration Medical Center, White River Junction, VT, USA.
Kara CavuotoBascom Palmer Eye Institute, University of Miami, Miami, FL, USA.
Annette K HoskinSave Sight Institute, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-7732-0323
Andrés Rousselot AscarzaConsultorios Oftalmológicos Benisek-Ascarza, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0003-2341-0988
William G Felipe Dhawahir-ScalaManchester Royal Eye Hospital, Manchester, UK.
Gangadhara SundarDepartment of Ophthalmology, National University Hospital, Singapore, Singapore.
Robert A MazzoliVision Center of Excellence, Research & Development Directorate (J-9), Defence Health Agency, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4418-5062
Peter ShahBirmingham Institute for Glaucoma Research, Birmingham, UK.
Malcolm WoodcockWorcestershire Acute Hospitals NHS Trust, Worcester, UK.
Ferenc KuhnHelen Keller Eye Research Foundation, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-9085-4875
Renata Sm GomesNorthern Hub for Veterans and Military Families Research, Northumbria University, Newcastle, UK.
Grant A JustinVision Center of Excellence, Research & Development Directorate (J-9), Defence Health Agency, Baltimore, MD, USA.
Richard J BlanchUniformed Services University of the Health Sciences, Bethesda, MD, USA. blanchrj@bham.ac.uk.ORCID http://orcid.org/0000-0002-6142-3280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proliferative Vitreoretinopathy (PVR) is the most common cause of surgical failure after retinal detachment (RD) repair, complicating up to 10% of spontaneous RD repairs and 50% of open globe injury-related RD. Early surgical intervention is currently the only intervention that reduces PVR incidence. An effective non-surgical intervention would be valuable in reducing PVR incidence and/or severity, particularly where access to surgery is limited or may be delayed. To define the evidence base for non-surgical management options to prevent and treat Proliferative Vitreoretinopathy (PVR) in retinal detachment and trauma, we searched PubMed, Clinicaltrials.gov, Medline and CINAHL for randomised controlled trials (RCTs) of non-surgical interventions to prevent or treat established PVR with no restriction on language or start date up until November 2024. All non-surgical interventions were considered with no restrictions. We considered outcomes of post-operative PVR (including retinal reattachment rate) and visual acuity and performed Risk of Bias (RoB) assessments using the Cochrane RoB2 tool. We identified 27 papers which included 1981 patients in studies of primary prevention and 1394 patients in studies of treatment of established PVR. While several studies of various agents individually demonstrated some improvements, the reviewers found concerns with RoB and the results were not replicated in the larger included studies. Multiple studies have investigated non-surgical interventions for PVR after RRD repair and trauma, but none have yet demonstrated clinically significant, repeatable benefits. Improved understanding of PVR pathobiology, along with larger prospective studies of existing preventative strategies may lead to the development of newer and more effective interventions.

Indexed as

Vitreoretinopathy, ProliferativeHumansRetinal DetachmentVisual Acuity

Identifiers

PMID40437039
PMCPMC12274627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.